Monday, November 3, 2008

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

From http://www.unboundmedicine.com/medline/ebm/record/18957500/full_citation/The_medical_treatment_of_Cushing%27s_disease:_effectiveness_of_chronic_treatment_with_the_dopamine_agonist_cabergoline_in_patients_unsuccessfully_treated_by_surgery

Title
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

Author(s)
Pivonello R, De Martino MC, Cappabianca P, de Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A

Institution
Department of Molecular and Clinical Endocrinology and Oncology [R.P., M.C.D.M., M.D.L., A.F., G.L., A.C.], and Neurosurgery [P.C], "Federico II" University, Naples, Italy and Department of Internal Medicine [R.P., L.J.H., S.W.J.L.], Erasmus Medical Center, Rotterdam, The Netherlands.

Source
J Clin Endocrinol Metab 2008 Oct 28.

 

Abstract
Background: The role of dopamine agonists in the treatment of Cushing's disease (CD) has been previously debated. Aim: The aim of this study was to evaluate the effectiveness of short-term (3 months) and long-term (12-24 months) treatment with cabergoline in patients with CD.

 

Patients and Methods: Twenty patients with CD unsuccessfully treated by surgery entered the study. Cabergoline was administered at an initial dose of 1 mg/week, with a monthly increase of 1 mg, until urinary cortisol levels normalized or the maximal dose of 7 mg/week was achieved. The responsiveness to treatment was evaluated according to changes in urinary cortisol excretion: a decrease greater than 25% was considered as a partial response, whereas complete normalization was considered as a full response at short-term evaluation; persistence of normal cortisol excretion was the only criterion to evaluate the response at long-term evaluation.


Results: After short-term treatment, 15 (75%) patients were responsive to cabergoline treatment. Among these, normalization of cortisol excretion was maintained in 10 whereas treatment escape was observed in 5 patients after 6-18 months. Among the 10 long-term responsive patients, eight were followed for 24 months, whereas the remaining 2 were followed for 12 months, due to cabergoline withdrawal for intolerance. A sustained control of cortisol secretion for 24 months of cabergoline treatment at the maximal dose, ranging from 1 to 7 mg/week (median: 3.5 mg/week) without significant side effects, was obtained in 8/20 (40%) patients.


Conclusions: The results of this study demonstrated that cabergoline treatment is effective in controlling cortisol secretion for at least 1-2 years in more than one third of a limited population of patients with CD. If this evidence is confirmed by additional studies, this agent may be considered as a useful treatment option in patients with CD who are unsuccessfully treated by neurosurgery.

Language
ENG

Pub Type(s)
JOURNAL ARTICLE

PubMed ID
18957500